Products
Mometasone furoate is commercially available as a cream, ointment, emulsion, and solution (Elocom, Monovo, Ovixan). It has been approved in many countries since 1989. This article refers to use on the skin. Nasal sprays are also available; see mometasone nasal spray. In 2020, a fixed combination with indacaterol was approved for asthma therapy (Atectura Breezhaler). Finally, a combination of indacaterol with glycopyrronium bromide and mometasone furoate was also registered for asthma treatment in 2020 (Enerzair Breezhaler).
Structure and properties
Mometasone (C22H28Cl2O4, Mr = 427.4 g/mol) is present in drugs as mometasone furoate, a white powder that is practically insoluble in water. It is a furan derivative and a chlorinated glucocorticoid.
Effects
Mometasone furoate (ATC D07AC13) has potent antiallergic, antiinflammatory, and immunosuppressive properties. The effects are due to binding to the intracellular glucocorticoid receptor.
Indications
For the treatment of inflammatory, noninfectious skin conditions that respond to glucocorticoids, for example, eczema, atopic dermatitis, psoriasis, and allergic contact dermatitis.
Dosage
According to the SmPC. Medicines are usually applied once daily and rubbed in gently. The duration of treatment should be kept short and not exceed two to three weeks. Do not apply over large areas or under occlusion.
Contraindications
- Hypersensitivity
- Skin infections
- Skin ulcers
- Rosacea
- Perioral dermatitis
- Vaccination reactions
- Application in the eye or near the eye
For full precautions, see the drug label.
Interactions
Interactions with other drugs are not known when used on the skin.
Adverse effects
The most common possible adverse effects include local skin reactions such as irritation, burning, itching, skin dryness, rash, and hypersensitivity reactions. Skin lesions are possible with improper use.
